Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification
- PMID: 23091029
- PMCID: PMC3511149
- DOI: 10.1073/pnas.1208215109
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification
Abstract
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. MYCN (V-myc myelocytomatosis viral-related oncogene, neuroblastoma derived [avian]) is amplified in 20% of neuroblastomas, and these tumors carry a poor prognosis. However, tumors without MYCN amplification also may have a poor outcome. Here, we identified downstream targets of MYCN by shRNA-mediated silencing MYCN in neuroblastoma cells. From these targets, 157 genes showed an expression profile correlating with MYCN mRNA levels in NB88, a series of 88 neuroblastoma tumors, and therefore represent in vivo relevant MYCN pathway genes. This 157-gene signature identified very poor prognosis tumors in NB88 and independent neuroblastoma cohorts and was more powerful than MYCN amplification or MYCN expression alone. Remarkably, this signature also identified poor outcome of a group of tumors without MYCN amplification. Most of these tumors have low MYCN mRNA levels but high nuclear MYCN protein levels, suggesting stabilization of MYCN at the protein level. One tumor has an MYC amplification and high MYC expression. Chip-on-chip analyses showed that most genes in this signature are directly regulated by MYCN. MYCN induces genes functioning in cell cycle and DNA repair while repressing neuronal differentiation genes. The functional MYCN-157 signature recognizes classical neuroblastoma with MYCN amplification, as well as a newly identified group marked by MYCN protein stabilization.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Comment in
-
Redefining functional MYCN gene signatures in neuroblastoma.Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19041-2. doi: 10.1073/pnas.1217598109. Epub 2012 Nov 8. Proc Natl Acad Sci U S A. 2012. PMID: 23139408 Free PMC article. No abstract available.
References
-
- Park JR, Eggert A, Caron H. Neuroblastoma: Biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24(1):65–86. - PubMed
-
- Lutz W, et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996;13(4):803–812. - PubMed
-
- Jiang R, Xue S, Jin Z. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo. Biochem Biophys Res Commun. 2011;410(2):364–370. - PubMed
-
- Bell E, et al. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010;293(2):144–157. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases